← Human Trials & Peer-Reviewed Studies
Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities
Plain-language guide to PMID 24092547 (2014): randomized controlled trial study of Octreotide and Somatostatin in 37 patients, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 24092547
- Journal
- European journal of endocrinology
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Olarescu NC et al. (6 authors)
- DOI
- 10.1530/EJE-13-0523
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide and Somatostatin in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
To test if GH/IGF1 promotes inflammation in adipocytes, and if this is relevant for systemic insulin resistance in acromegaly.
Furthermore, to investigate the effect of treatment modalities (transsphenoidal surgery (TS), somatostatin analogs (SAs), and pegvisomant (PGV)) on glucose metabolism and inflammatory biomarkers in acromegaly.
Who Took Part
The study group was 37 patients.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
Body composition, glucose metabolism, and circulating adipokines (adiponectin (AD), high-molecular weight AD (HMWAD), leptin, vascular endothelial growth factor-A (VEGF-A), monocyte chemotactic protein 1 (MCP1), and thioredoxin (TRX)) were measured in 37 patients with active acromegaly before and after treatment.
How the Study Was Run
In design terms this was a randomized study.
The patients were allocated by chance, so the Octreotide group and the comparison group should start out alike.
The in vitro effects of GH/IGF1 on gene expression of adipokines in human adipocytes were investigated.
What Was Measured
PubMed files the paper under topics including Acromegaly, Adiposity, Cells, Cultured, Chemokine CCL2, Cohort Studies, Gene Expression Regulation and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized study of Octreotide and Somatostatin in 37 patients in people with insulin resistance, prediabetes & type 2 diabetes.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (European journal of endocrinology), a journal based in England.
More context: the Octreotide compound page and the Somatostatin compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
- Insulin resistance, prediabetes & type 2 diabetes research
- Octreotide in the library
- Somatostatin in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.